125 related articles for article (PubMed ID: 24308434)
1. Bendamustine and melphalan kill myeloma cells similarly through reactive oxygen species production and activation of the p53 pathway and do not overcome resistance to each other.
Surget S; Lemieux-Blanchard E; Maïga S; Descamps G; Le Gouill S; Moreau P; Amiot M; Pellat-Deceunynck C
Leuk Lymphoma; 2014 Sep; 55(9):2165-73. PubMed ID: 24308434
[TBL] [Abstract][Full Text] [Related]
2. Decitabine and Melphalan Fail to Reactivate p73 in p53 Deficient Myeloma Cells.
Gillardin PS; Descamps G; Maiga S; Tessoulin B; Djamai H; Lucani B; Chiron D; Moreau P; Le Gouill S; Amiot M; Pellat-Deceunynck C; Moreau-Aubry A
Int J Mol Sci; 2017 Dec; 19(1):. PubMed ID: 29295500
[TBL] [Abstract][Full Text] [Related]
3. Bendamustine induces G2 cell cycle arrest and apoptosis in myeloma cells: the role of ATM-Chk2-Cdc25A and ATM-p53-p21-pathways.
Gaul L; Mandl-Weber S; Baumann P; Emmerich B; Schmidmaier R
J Cancer Res Clin Oncol; 2008 Feb; 134(2):245-53. PubMed ID: 17653574
[TBL] [Abstract][Full Text] [Related]
4. PRIMA-1Met induces myeloma cell death independent of p53 by impairing the GSH/ROS balance.
Tessoulin B; Descamps G; Moreau P; Maïga S; Lodé L; Godon C; Marionneau-Lambot S; Oullier T; Le Gouill S; Amiot M; Pellat-Deceunynck C
Blood; 2014 Sep; 124(10):1626-36. PubMed ID: 25006124
[TBL] [Abstract][Full Text] [Related]
5. Cell death via DR5, but not DR4, is regulated by p53 in myeloma cells.
Surget S; Chiron D; Gomez-Bougie P; Descamps G; Ménoret E; Bataille R; Moreau P; Le Gouill S; Amiot M; Pellat-Deceunynck C
Cancer Res; 2012 Sep; 72(17):4562-73. PubMed ID: 22738917
[TBL] [Abstract][Full Text] [Related]
6. RITA (Reactivating p53 and Inducing Tumor Apoptosis) is efficient against TP53abnormal myeloma cells independently of the p53 pathway.
Surget S; Descamps G; Brosseau C; Normant V; Maïga S; Gomez-Bougie P; Gouy-Colin N; Godon C; Béné MC; Moreau P; Le Gouill S; Amiot M; Pellat-Deceunynck C
BMC Cancer; 2014 Jun; 14():437. PubMed ID: 24927749
[TBL] [Abstract][Full Text] [Related]
7. Bendamustine overcomes resistance to melphalan in myeloma cell lines by inducing cell death through mitotic catastrophe.
Cives M; Ciavarella S; Rizzo FM; De Matteo M; Dammacco F; Silvestris F
Cell Signal; 2013 May; 25(5):1108-17. PubMed ID: 23380051
[TBL] [Abstract][Full Text] [Related]
8. Whole-exon sequencing of human myeloma cell lines shows mutations related to myeloma patients at relapse with major hits in the DNA regulation and repair pathways.
Tessoulin B; Moreau-Aubry A; Descamps G; Gomez-Bougie P; Maïga S; Gaignard A; Chiron D; Ménoret E; Le Gouill S; Moreau P; Amiot M; Pellat-Deceunynck C
J Hematol Oncol; 2018 Dec; 11(1):137. PubMed ID: 30545397
[TBL] [Abstract][Full Text] [Related]
9. The checkpoint kinase inhibitor AZD7762 potentiates chemotherapy-induced apoptosis of p53-mutated multiple myeloma cells.
Landau HJ; McNeely SC; Nair JS; Comenzo RL; Asai T; Friedman H; Jhanwar SC; Nimer SD; Schwartz GK
Mol Cancer Ther; 2012 Aug; 11(8):1781-8. PubMed ID: 22653969
[TBL] [Abstract][Full Text] [Related]
10. Assessment of TP53 lesions for p53 system functionality and drug resistance in multiple myeloma using an isogenic cell line model.
Munawar U; Roth M; Barrio S; Wajant H; Siegmund D; Bargou RC; Kortüm KM; Stühmer T
Sci Rep; 2019 Dec; 9(1):18062. PubMed ID: 31792264
[TBL] [Abstract][Full Text] [Related]
11. Curcumin induces cell death of the main molecular myeloma subtypes, particularly the poor prognosis subgroups.
Gomez-Bougie P; Halliez M; Maïga S; Godon C; Kervoëlen C; Pellat-Deceunynck C; Moreau P; Amiot M
Cancer Biol Ther; 2015; 16(1):60-5. PubMed ID: 25517601
[TBL] [Abstract][Full Text] [Related]
12. Everolimus enhances the cytotoxicity of bendamustine in multiple myeloma cells through a network of pro-apoptotic and cell-cycle-progression regulatory proteins.
Lu B; Li J; Pan J; Huang B; Liu J; Zheng D
Acta Biochim Biophys Sin (Shanghai); 2013 Aug; 45(8):683-91. PubMed ID: 23688587
[TBL] [Abstract][Full Text] [Related]
13. Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines.
Strumberg D; Harstrick A; Doll K; Hoffmann B; Seeber S
Anticancer Drugs; 1996 Jun; 7(4):415-21. PubMed ID: 8826610
[TBL] [Abstract][Full Text] [Related]
14. Blockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma.
Hunsucker SA; Magarotto V; Kuhn DJ; Kornblau SM; Wang M; Weber DM; Thomas SK; Shah JJ; Voorhees PM; Xie H; Cornfeld M; Nemeth JA; Orlowski RZ
Br J Haematol; 2011 Mar; 152(5):579-92. PubMed ID: 21241278
[TBL] [Abstract][Full Text] [Related]
15. PJ34, a poly(ADP-ribose) polymerase (PARP) inhibitor, reverses melphalan-resistance and inhibits repair of DNA double-strand breaks by targeting the FA/BRCA pathway in multidrug resistant multiple myeloma cell line RPMI8226/R.
Xiong T; Wei H; Chen X; Xiao H
Int J Oncol; 2015 Jan; 46(1):223-32. PubMed ID: 25351371
[TBL] [Abstract][Full Text] [Related]
16. Amiloride, An Old Diuretic Drug, Is a Potential Therapeutic Agent for Multiple Myeloma.
Rojas EA; Corchete LA; San-Segundo L; Martínez-Blanch JF; Codoñer FM; Paíno T; Puig N; García-Sanz R; Mateos MV; Ocio EM; Misiewicz-Krzeminska I; Gutiérrez NC
Clin Cancer Res; 2017 Nov; 23(21):6602-6615. PubMed ID: 28790111
[No Abstract] [Full Text] [Related]
17. Modulation of cell metabolic pathways and oxidative stress signaling contribute to acquired melphalan resistance in multiple myeloma cells.
Zub KA; Sousa MM; Sarno A; Sharma A; Demirovic A; Rao S; Young C; Aas PA; Ericsson I; Sundan A; Jensen ON; Slupphaug G
PLoS One; 2015; 10(3):e0119857. PubMed ID: 25769101
[TBL] [Abstract][Full Text] [Related]
18. Down-regulation of CD98 in melphalan-resistant myeloma cells with reduced drug uptake.
Harada N; Nagasaki A; Hata H; Matsuzaki H; Matsuno F; Mitsuya H
Acta Haematol; 2000; 103(3):144-51. PubMed ID: 10940652
[TBL] [Abstract][Full Text] [Related]
19. Knockdown of DEPTOR inhibits cell proliferation and increases chemosensitivity to melphalan in human multiple myeloma RPMI-8226 cells via inhibiting PI3K/AKT activity.
Zhang HR; Chen JM; Zeng ZY; Que WZ
J Int Med Res; 2013 Jun; 41(3):584-95. PubMed ID: 23613505
[TBL] [Abstract][Full Text] [Related]
20. A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells.
Gullà A; Di Martino MT; Gallo Cantafio ME; Morelli E; Amodio N; Botta C; Pitari MR; Lio SG; Britti D; Stamato MA; Hideshima T; Munshi NC; Anderson KC; Tagliaferri P; Tassone P
Clin Cancer Res; 2016 Mar; 22(5):1222-33. PubMed ID: 26527748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
